Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Ginkgo Bioworks Holdings

Healthcare US DNA

8.73USD
-0.6(6.43%)

Last update at 2026-06-03T20:25:00Z

Day Range

8.469.16
LowHigh

52 Week Range

5.3717.58
LowHigh

Fundamentals

  • Previous Close 9.33
  • Market Cap494.16M
  • Volume1336314
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-267.82200M
  • Revenue TTM170.16M
  • Revenue Per Share TTM3.07
  • Gross Profit TTM 123.18M
  • Diluted EPS TTM-5.64

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -313.60000M -547.50800M -892.94000M -2121.39900M -1838.12200M
Minority interest - 0.00000M -2.39000M 1.44M -6.59500M
Net income -312.76300M -547.02900M -892.86900M -2106.37200M -1836.64200M
Selling general administrative 183.29M 246.16M 385.02M 1429.80M 862.95M
Selling and marketing expenses - - 95.97M - -
Gross profit 138.63M 188.49M 197.45M 273.49M 184.15M
Reconciled depreciation 58.99M 63.02M 75.21M 44.42M 29.08M
Ebit -313.60000M -547.41400M -892.84700M -2208.95200M -1828.46700M
Ebitda -254.61000M -484.39400M -821.29300M -2180.39400M -1877.57100M
Depreciation and amortization 58.99M 63.02M 71.55M 28.56M -49.10400M
Non operating income net other - - - 87.55M -
Operating income -315.27800M -559.75700M -864.40600M -2208.95200M -1828.46700M
Other operating expenses 485.43M 786.80M 1115.86M 2686.66M 2142.30M
Interest expense 0.00000M 0.09M 0.09M 0.11M 2.37M
Tax provision -0.83700M -0.47900M -14.64300M -15.02700M -1.48000M
Interest income 22.62M 38.61M 57.22M 20.26M 0.84M
Net interest income 22.62M 38.52M 55.25M 20.16M -1.53600M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.83700M -0.47900M -0.07100M -15.02700M -1.48000M
Total revenue 170.16M 227.04M 251.46M 477.71M 313.84M
Total operating expenses 453.91M 748.25M 1061.86M 2482.44M 2012.61M
Cost of revenue 31.52M 38.55M 54.01M 204.22M 129.69M
Total other income expense net 1.68M 12.25M -28.53400M 87.55M -9.65500M
Discontinued operations - - - - -
Net income from continuing ops -312.76300M -547.02900M -854.25300M -2106.37200M -1836.64200M
Net income applicable to common shares -312.76300M -547.02900M -892.86900M -2104.92900M -1830.04700M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1119.70M 1377.45M 1665.34M 2539.32M 2070.99M
Intangible assets 56.92M 72.51M 82.74M 111.04M 21.64M
Earning assets - - - - -
Other current assets 25.19M 18.73M 39.73M 49.02M 0.70M
Total liab 611.11M 661.39M 568.19M 803.04M 503.61M
Total stockholder equity 508.59M 716.06M 1097.15M 1736.28M 1505.37M
Deferred long term liab - - - 174.77M 174.74M
Other current liab 66.46M 33.53M 88.57M 114.69M 92.58M
Common stock 0.00600M 0.00500M 0.00500M 0.19M 0.16M
Capital stock 0.00600M 0.00500M 0.20M 0.19M 0.16M
Retained earnings -6150.32000M -5837.55700M -5290.52800M -4397.65900M -2297.92500M
Other liab - - - 216.83M 346.57M
Good will - 0.00000M 49.24M 60.21M 21.31M
Other assets 47.17M 41.17M 42.22M 88.72M 43.99M
Cash 167.20M 561.57M 944.07M 1315.79M 1550.00M
Cash and equivalents 167.20M 561.57M 944.07M 1315.79M 1550.00M
Total current liabilities 95.97M 107.27M 163.86M 172.96M 134.76M
Current deferred revenue 18.95M 30.60M 48.49M 47.82M 33.24M
Net debt 249.88M -93.84100M -704.76400M -902.53600M -1526.97400M
Short term debt 0.00000M 28.96M 17.47M 29.33M 0.75M
Short long term debt - - - - -
Short long term debt total 417.08M 467.73M 239.31M 413.26M 23.03M
Other stockholder equity 6657.05M 6555.42M 6386.19M 6133.75M 3804.84M
Property plant equipment 528.70M 598.15M 397.22M 715.53M 145.77M
Total current assets 471.84M 602.74M 1001.75M 1450.08M 1723.05M
Long term investments 14.88M 48.47M 77.91M 113.73M 102.04M
Net tangible assets - - - 1565.03M 1462.41M
Short term investments 255.42M 0.00000M -0.65400M - -
Net receivables 24.03M 22.44M 17.90M 80.91M 149.90M
Long term debt - - - - -
Inventory - - 0.05M 4.36M 3.36M
Accounts payable 10.57M 14.17M 9.32M 10.45M 8.19M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - 62.01M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.85M -1.80600M 1.48M -2.63200M -1.71500M
Additional paid in capital - - - - -
Common stock total equity - - - 0.19M 0.16M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -4397.65900M -2297.92500M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 47.17M 55.34M 58.71M 202.46M 43.99M
Deferred long term asset charges - - - - -
Non current assets total 647.86M 774.71M 663.59M 1089.24M 347.94M
Capital lease obligations 439.88M 467.73M 241.77M 413.26M 23.03M
Long term debt total 0.00000M 0.03M 0.48M 0.00000M 22.28M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -233.24800M -62.23600M -4.27900M -67.39400M -5.00000M
Change to liabilities - - - -50.45200M -12.74500M
Total cashflows from investing activities -240.28900M -62.23600M -80.69300M -67.39400M -73.25700M
Net borrowings -0.35400M -0.89700M -1.29500M 97.84M -1.12300M
Total cash from financing activities 17.77M -1.73900M -3.21600M 95.34M 1534.14M
Change to operating activities - - - -44.93300M 65.93M
Net income -312.76300M -547.02900M -892.86900M -2106.37200M -1836.64200M
Change in cash -393.17800M -383.84100M -379.99700M -223.34700M 1207.05M
Begin period cash flow 567.41M 989.58M 1369.58M 1592.93M 385.88M
End period cash flow 174.23M 605.74M 989.58M 1369.58M 1592.93M
Total cash from operating activities -171.05900M -319.58500M -295.50000M -252.19800M -253.81800M
Issuance of capital stock 19.47M 0.00000M 0.00000M 99.30M 0.00000M
Depreciation 58.99M 63.02M 71.55M 44.42M 29.08M
Other cashflows from investing activities 0.62M 1.19M -1.34000M -15.12300M -16.73600M
Dividends paid - - - - -
Change to inventory - - - 0.16M -0.62600M
Change to account receivables -1.47300M -4.72500M 50.07M 55.02M -114.09400M
Sale purchase of stock 19.47M 0.08M -0.02300M 99.54M -24.99800M
Other cashflows from financing activities -1.34000M -0.92200M -1.89800M -2.72900M 1560.27M
Change to netincome - - - 1859.54M 1608.69M
Capital expenditures 7.67M 62.54M 40.80M 52.27M 56.52M
Change receivables - - - 55.02M -114.09400M
Cash flows other operating - - - -58.80900M -34.69500M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -224.25500M 1207.07M
Change in working capital -44.08800M -89.67000M 29.84M -37.00600M -61.53700M
Stock based compensation 81.55M 112.34M 229.88M 1930.64M 1606.02M
Other non cash items 46.62M 142.69M 266.89M -69.27500M -20.94700M
Free cash flow -178.72400M -382.12600M -336.30100M -304.46900M -310.33900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DNA
Ginkgo Bioworks Holdings		 -0.6 6.43% 8.73 - - 2.90 0.97 3.01 -1.7918
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Ginkgo Bioworks Holdings

27 Drydock Avenue, Boston, MA, United States, 02210

Key Executives

Name Title Year Born
Dr. Jason Kelly Founder, CEO & Director 1981
Dr. Reshma P. Shetty Founder, Pres, COO & Director 1981
Mr. Mark E. Dmytruk Chief Financial Officer 1971
Mr. Thomas Knight Jr. Founder NA
Mr. Austin Che Founder, Head of Strategy & Treasurer NA
Mr. Bartholomew Canton Founder, CTO & Sec. NA
Marie E Fallon Chief Accounting Officer NA
Karen Tepichin Gen. Counsel & Sec. NA
Ms. Anna Marie Wagner Sr. VP of Corp. Devel. NA
Ms. Samantha Sutton Head of People NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.